Last reviewed · How we verify
NCT07298824
Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia
Phase 2 trial testing Investigational Bifidobacterium Preparation MR-61 in Myopia Progressing in 164 participants. Currently enrolling.
1 July 2027
Quick facts
| Lead sponsor | Second Affiliated Hospital of Nanchang University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 164 |
| Start date | 1 October 2025 |
| Primary completion | 1 July 2027 |
| Estimated completion | 1 July 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Investigational Bifidobacterium Preparation MR-61 — full drug profile →
- Placebo for MR-61
Conditions studied
- Myopia Progressing — all drugs for Myopia Progressing →
Sponsor
Second Affiliated Hospital of Nanchang University
Who can join
Adults 3 to 18, any sex, with Myopia Progressing. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To investigate whether probiotic MR-61 can assist in slowing down the progression rate of myopia (a prospective randomized controlled study).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07298824
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myopia Progressing
Currently open trials in the same condition.
- NCT07585877 — Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression · NA · active not recruiting
- NCT06927414 — Light Diffraction Glasses in Preventing and Controlling Myopia in Adolescents · NA · active not recruiting
Other Second Affiliated Hospital of Nanchang University trials
Trials by the same sponsor.
- NCT07346794 — The Underlying Neural Mechanism of TMS in Improving the Imbalance of "Microbiota-brain-gut Axis" in Alzheimer 's Disease · NA · not yet recruiting
- NCT07398599 — Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metast · NA · recruiting
- NCT07401784 — Efficacy and Safety Evaluation of Remote Ischemic Adaptation ( Intermittent Pressure Stimulation ) in the Treatment of I · NA · not yet recruiting
- NCT07290699 — Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period · Phase 4 · not yet recruiting
- NCT07295444 — A Clinical Study Evaluating the Efficacy and Safety of CreNeuriS CNS Herbal Nutrition Capsules for Participants With Mil · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07298824 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Nanchang University
- Last refreshed: 23 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07298824.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing